Aurobindo Pharma (BOM:524804) ROCE %: 13.73% (As of Mar. 2026)

What is Aurobindo Pharma ROCE %?

Aurobindo Pharma BOM:524804 +0.47% 85 ROCE % is 13.73% as of Mar. 2026. GuruFocus rates BOM:524804 with a GF Score™ of 85/100 and a GF Value™ of ₹1,325.21 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aurobindo Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was 13.73%.

Aurobindo Pharma (BOM:524804) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aurobindo Pharma ROCE % Related Terms

Aurobindo Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Aurobindo Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma ROCE % Chart

Aurobindo Pharma Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

13.93

10.12

15.17

16.25

14.55

Aurobindo Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															16.52	14.87	14.81	15.45	13.73

85GF Score

Aurobindo Pharma Ltd BOM:524804

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aurobindo Pharma ROCE % Calculation

Aurobindo Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	54958.2	/	( ( (497849.7 - 146823.4)	+	(585021.5 - 180390.1) )	/ 2 )
	=	54958.2	/	( (351026.3	+	404631.4)	/ 2 )
	=	54958.2	/	377828.85
	=	14.55 %

Aurobindo Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	55552.8	/	( ( (0 - 0)	+	(585021.5 - 180390.1) )	/ 1 )
	=	55552.8	/	( ( 0	+	404631.4 )	/ 1 )
	=	55552.8	/	404631.4
	=	13.73 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 13.73% mean?

Aurobindo Pharma (BOM:524804) has a ROCE % of 13.73% as of Mar. 2026.

Is Aurobindo Pharma's ROCE % too high?

Aurobindo Pharma's current ROCE % is 13.73%. The Drug Manufacturers industry median ROCE % is 7.03. Aurobindo Pharma's value of 13.73% is 95.3% above this industry median. Overall, Aurobindo Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aurobindo Pharma's ROCE % compare to ZTS and UTHR?

Aurobindo Pharma's ROCE % of 13.73% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Aurobindo Pharma's value of 13.73% is 95.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurobindo Pharma's current ROCE % of 13.73% is 95.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current ROCE % is 13.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aurobindo Pharma stock overvalued right now?

Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,325.21, compared to a current price of ₹1,560.05 — trading 17.7% above its estimated fair value. The current ROCE % is 13.73% and 95.3% above the Drug Manufacturers industry median of 7.03. Aurobindo Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current ROCE % is 13.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,560.05 is trading 17.7% above its estimated GF Value™ of ₹1,325.21. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

ROCE %: 13.73%
GF Value™: ₹1,325.21 vs. price of ₹1,560.05 (17.7% above fair value)
GF Score™: 85/100 with 7 warning signs
Industry Position: 95.3% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aurobindo Pharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:540222 BOM:543904 BOM:500257 BOM:532321 BOM:500124 NSE:ALKEM BOM:500087 BOM:532296 BOM:500488 BOM:524494 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges AUROPHARMA:India

Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032

Website https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

85GF Score

Get the complete analysis for BOM:524804

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,560.05

Price

₹1,325.21

GF Value

View BOM:524804 Analysis

See ROCE % data for all stocks →